Mirabegron + Solifenacin succinate
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Urologic Diseases
Conditions
Urologic Diseases, Urinary Bladder, Overactive, Urinary Bladder Diseases
Trial Timeline
Jun 12, 2012 → Apr 24, 2013
NCT ID
NCT01638000About Mirabegron + Solifenacin succinate
Mirabegron + Solifenacin succinate is a phase 3 stage product being developed by Astellas Pharma for Urologic Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT01638000. Target conditions include Urologic Diseases, Urinary Bladder, Overactive, Urinary Bladder Diseases.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01638000 | Phase 3 | Completed |
Competing Products
16 competing products in Urologic Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| pemetrexed + cisplatin | Eli Lilly | Phase 1/2 | 41 |
| Mirabegron + Solifenacin succinate + Placebo | Astellas Pharma | Phase 2 | 52 |
| Gemcitabine | Eli Lilly | Phase 2 | 52 |
| pemetrexed | Eli Lilly | Phase 2 | 52 |
| ALIMTA + gemcitabine | Eli Lilly | Phase 2 | 52 |
| BBI503 | Sumitomo Pharma | Phase 2 | 52 |
| Pembrolizumab Injection [Keytruda] | Merck | Phase 2 | 52 |
| Carboplatin/Paclitaxel + Pembrolizumab | Merck | Phase 2 | 52 |
| zoledronic acid | Novartis | Phase 2 | 52 |
| mycophenolate mofetil | Roche | Phase 1 | 33 |
| Cetuximab + Paclitaxel | Bristol Myers Squibb | Phase 2 | 51 |
| Nivolumab + Relatlimab | Bristol Myers Squibb | Phase 2 | 51 |
| CBT101 + Placebo | Brain Biotech | Phase 1 | 25 |
| OGX-427 600 mg + OGX-427 1000 mg + Placebo + Gemcitabine + Cisplatin + Carboplatin | Achieve Life Sciences | Phase 2 | 44 |
| S-8184 Paclitaxel Injectable Emulsion + Experimental Arm: TOCOSOL Paclitaxel | Achieve Life Sciences | Phase 2 | 44 |
| Stem Cell | Brain Biotech | Phase 1 | 25 |